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It is not yet known the extent to which the environment adversely affects the health of the
developing individual. Difficulties in this determination are the problems of a) the assessment of
exposure, b) the long latency of many diseases induced by the environment, c) the number of
confounding exposures, and d) the extrapolation of animal models to critical stages of human
development. Biomarkers have the potential to be quantitative dosimeters of exposure and
biologic effective dose, as well as early warning signals of biologic effect. Biomarkers may
document interindividual susceptibilities, as well as defining critical windows of exposure. To be
useful, biomarkers need to be validated in terms of their specificity and sensitivity. Biomarkers
are useful across all disciplines including asthma and respiratory problems, developmental
neurotoxicity, childhood cancer, and endocrine disruptors. Biomarkers have not been developed
nor used widely in pediatric environmental health. Research by our group and others has
documented the validity of biomarkers in pediatric environmental health. Advances in the field of
biomarkers may have important implications for the detection, prevention, and treatment of
environmentally induced diseases in children. Ongoing validation of promising biomarkers
should be a research priority. Environ Health Perspect 106(Suppl 3):813-816 (1998).
http.//ehpnetl.niehs.nih.gov/docs/1998/Suppl-3/813-816bearer/abstract.html
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Introduction
Developing individuals (embryos, fetuses,
newborns, infants, children, and adoles-
cents) are a uniquely susceptible popula-
tion to insults from environmental hazards
(1,2). Their increased susceptibility can
arise from increased exposure to environ-
mental toxins, increased exposure of indi-
vidual organ systems from differences in
distribution oftoxins, immaturity ofmeta-
bolic pathways, immaturity of excretory
pathways, alterations in target organ sus-
ceptibility, and a longer life span in which
to express illness. Although the enhanced
susceptibility of infants and children to
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environmental toxicants has been shown in
multiple studies, the nature and extent of
pediatric illness secondary to environmental
exposure has not been well characterized.
There are several reasons for this deficiency.
First, documentation ofexposure is difficult
in the fetal and pediatric population.
Pregnant women and children do not wear
personal monitoring devices as do workers
in an occupational exposure setting.
Modeling ofexposure is difficult; there are
few studies documenting where children
spend their time. Even in situations with
known exposures, the individual dose to a
child is difficult to document. The long
latency of many environmentally induced
diseases makes their etiology difficult to
determine. Thus, retrospective studies are
difficult to conduct. An individual is also
exposed to more than one environmental
toxicant and probably to other agents,
which may confound the association ofone
toxicant to an illness. Extrapolation of ani-
mal models to human children is difficult.
Many ofthe critical stages ofdevelopment
are not well characterized in animals. For
example, an exposure that occurs during
puberty in children may be difficult
to model in an animal. Finally, classic
epidemiology has limitations in sensitivity.
For example, if thalidomide had caused
mental retardation, the rarity ofthe exposure
would never have significantly increased
the rate ofmental retardation above back-
ground rates, and hence, thalidomide
would not have been recognized as a ter-
atogen (3). Biomarkers have the potential
to overcome many of these difficulties.
They may be used to identify the early
stages ofhealth impairment and to under-
stand basic mechanisms ofexposure and
response in research and medical practice.
Because of this potential, in 1986 the
National Academy of Sciences and the
National Research Council created three
subcommittees and an oversight committee
to evaluate the state ofknowledge ofbio-
markers in reproductive and developmental
toxicology (4), pulmonary toxicology (5),
and immunotoxicology (6).
What Are Biomarkers?
Biologic markers, or biomarkers, are
indicators ofvariation in cellular or bio-
chemical components or processes, struc-
ture, or function that are measurable in
biologic systems or samples. Biomarkers
are used widely throughout medicine. A
well-known example is the measurement of
creatinine in blood to assess kidney func-
tion. Biomarkers represent signals on a
continuum between health and disease
(Figure 1). A biomarker may not always
function at the same point on this contin-
uum, but may change roles as knowledge
of the environment-organism interaction
increases. A biomarker may also function
at more than one place on this continuum.
For example, blood lead concentration
serves as both a marker ofexposure (7) and
a marker ofneurotoxicity (8).
Three general categories ofbiomarkers
have been defined: biomarkers ofexposure
to chemical or physical agents, biomarkers
ofeffects ofthose exposures, and biomark-
ers ofsusceptibility. A biomarker ofexpo-
sure is an exogenous chemical or its
metabolite(s) or the product ofan interac-
tion between a xenobiotic agent and some
target molecule or cell that is measured in a
compartment within an organism. A bio-
logic marker ofeffect is a measurable alter-
ation ofan endogenous component within
an organism that, depending on magni-
tude, can be recognized as a potential or
established health impairment or disease. A
biomarker ofsusceptibility is an indicator
of an inherent or acquired property of an
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Figure 1. Simplified flow chart ofclasses of biologic markers (D). , indicates progression, if it occurs, to the
next class of marker.-- , indicates that individual susceptibility influences the rates of progression, as do
other variables described in the text. Biologic markers represent a continuum of changes, and the classification
of change may not always be distinct. From National Research Council (4); reproduced with permission from
National Academy Press.
organism to increase the internal dose ofa
xenobiotic or to alter the response to the
challenge ofexposure to a specific xenobi-
otic substance. Abiologic marker ofsuscep-
tibility may also be a marker ofresistance
when the internal dose or the health effect
is less than the general population in
children with this marker.
Biomarkers of Exposure
Biomarkers of exposure can be divided
into internal dosimeters or markers ofbio-
logically effective dose. An internal
dosimeter measures the amount of a toxi-
cant or its metabolite present in cells, tis-
sues, or body fluids. Several studies in
children have documented elevation in
such biomarkers with several different
types of exposures. For example, fetal
exposure to some chemicals has been
shown with cord blood measurements of
polychlorinated biphenyls (9) and coti-
nine (a metabolite ofnicotine) (10). We
have used cotinine in cord blood as a bio-
marker for maternal environmental
tobacco smoke exposure to show that this
exposure may increase the risk ofdeliver-
ing an infant with persistent pulmonary
hypertension of the newborn (10). Fetal
exposure can also be documented with
meconium analysis for drugs of abuse
(11), ethanol (12), and lead (13). In chil-
dren, blood lead concentration has been
used as a marker for lead exposure, and
urinary nitrophenol concentration has
been used as a marker for methyl
parathion exposure (14). Internal dosime-
ters take into account individual differ-
ences in absorption or bioaccumulation of
the xenobiotic in question and are rela-
tively easy to measure. However, they do
not provide information about the interac-
tion with critical cellular targets-the
biologic effective dose. For example, a
child 2 years of age and a newborn may
have the same blood lead concentration,
but the interaction ofthe lead with critical
sites in the central nervous system may be
greater for the newborn because ofthe lack
ofa blood-brain barrier.
The biologically effective dose is the
amount ofxenobiotic material that has
interacted with a critical molecular site
where the biologic effect is initiated.
Frequently, surrogates are used because of
lackofknowledge ofthe actual target mole-
cule and/or inaccessibility ofthe target tis-
sue, such as bone marrow or brain.
Examples ofthis type ofbiomarker are car-
cinogen-DNA adducts with specific car-
cinogens that are measured in white blood
cells (15). Because carcinogens are thought
to act through effects on DNA expression,
the measurement of carcinogen-DNA
adducts in white blood cells is a surrogate
for the measurement of the specific
DNA-carcinogen interaction initiating the
cancer in the target tissue. Carcinogen-pro-
tein adducts in blood have also been used as
surrogates for the biologically effective dose
in the target organ.
Biomarkers of Effects
Biomarkers of effects in an organism
after exposure to an environmental agent
can be categorized based on their relation-
ship to health status-from normal health,
to health impairment, to overt disease.
Therefore, there can be a wide spectrum
ofmeasurable effects: a) an alteration in a
tissue or organ; b) an early event in a
biologic process that is predictive ofdevel-
opment of a health impairment; c) a
health impairment or clinically recognized
disease; or d) a response peripheral or par-
allel to a disease process, but correlated
with it and thus usable in predicting
development ofa health impairment (4).
To summarize, a biomarker of an effect
can be any qualitative or quantitative alter-
ation that is predictive ofhealth impair-
ment resulting from exposure to an
exogenous agent. A wide variety of bio-
markers fall into this category. An example
ofa biomarker ofeffect is the alteration in
pulmonary function tests in children after
exposure to environmental tobacco smoke
(16). Another biomarker of effect is
hypoplasia of the corpus callosum in
infants exposed to ethanol in utero (17).
Biomarkers of effect are not chemical-
or agent-specific and can be affected by
other exposures in the environment or by
lifestyle. For example, nitrogen dioxide
can also alter pulmonary function tests
in children.
Biomarkers ofSusceptibility
Biomarkers of susceptibility indicate
individual factors that can affect response
to environmental agents. These individual
factors reflect variations between individu-
als in genetic structure. Typically, genetic
variability refers to variations in gene struc-
ture that occur in more than 1% of the
population (genetic polymorphisms) and
to those that occur in less than 1% ofthe
population (genetic mutations). For exam-
ple, blue eye color is a genetic polymor-
phism and albinism is a genetic mutation
(or inherited disease). Differences in gene
expression with stage ofdevelopment are
not considered to be genetic variabilities
but rather age-related variabilities. Some of
these variations in genetic structure make
the individual more susceptible to health
effects from environmental exposures.
These genetic variabilities occur in the
absence ofexposure, although exposure can
increase or decrease susceptibility to the
effects oflater exposure. An example would
be an exposure to a toxicant that induces
the enzyme responsible for its excretion. A
subsequent dose would be metabolized
more readily and hence cause less harm.
This is one explanation for the observed U-
shaped dose-response curve for some toxi-
cants that at low levels appear to have a
beneficial effect.
How do genetic variabilities increase/
decrease susceptibility to environmental
toxicants? In general, to develop a disease
from exposure to an environmental toxi-
cant, the following must occur: exposure to
the toxicant, absorption of the toxicant,
distribution of the toxicant in the body,
metabolism of the toxicant (activation,
deactivation), excretion of the toxicant,
interaction ofthe toxicant with the target
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molecule, damage ofthe target molecule,
and repair of the damaged molecule.
Genetic variability may increase suscepti-
bility to disease from an environmental
toxicant if any of these processes are
altered. Obvious examples are found in
individuals with inherited diseases.
Frequently the disease state presents fol-
lowing birth, when common environmen-
tal exposures occur. Such disease states are
easily recognized because of their acuity
and severity, for example, xeroderma pig-
mentosa and skin cancer from UV irradia-
tion (inability to repair DNA damage),
phenylketonuria and a diet with phenylala-
nine-containing proteins (inability to
metabolize phenylalanine), or glucose 6-
phosphate dehydrogenase deficiency and
methemoglobinemia from exposure to
naphthalene mothballs (inability to reduce
the oxidized iron in hemoglobin). More
difficult to detect are those genetic varia-
tions leading to genetic susceptibility in
individuals with common genetic polymor-
phisms. They are common because either
the increased susceptibility is to a rare envi-
ronmental exposure, or the disease states
are ofa more chronic or subacute nature.
For example, only newborns unable to
metabolize dilantin delivered to mothers
taking dilantin (a rare exposure) had fea-
tures ofphenytoin embryopathy. A bio-
marker ofthis susceptibility is the epoxide
hydrolase activity offetal amniocytes (18).
Recent advances in determining genetic
susceptibility are discussed by Suk and
Collman (19) and Whyatt et al. (20) in
this issue.
Validation of Biologic Markers
To validate the use of a biologic measure-
ment as a biomarker, it is necessary to
understand the relationship between the
marker and the event or condition of
interest. Determining the sensitivity and
specificity are critical components of the
validation process. Sensitivity refers to the
ability of a test to correctly identify those
with the condition or disease of interest.
Specificity refers to the ability of a test to
correctly identify those without the condi-
tion or disease of interest. Biomarkers of
exposure or effect must be validated in
terms of their ability to assess the true
exposure or disease (sensitivity) and their
ability to assess the lack ofexposure or dis-
ease (specificity). One ofthe primary pur-
poses of biomarkers in environmental
health research is to identify exposed
persons, so that risk can be predicted and
disease prevented. Validation ofbiomarkers
includes the backward process ofassociat-
ing a biomarker with exposure, and the
forward process of linking a biomarker
with effect. Appropriate validation for a
biomarker depends on its anticipated use.
A biomarker observed well before the
onset ofdisease may have a low predictive
value as a biomarker of effect, but be
very useful as a biomarker of exposure,
enabling long-term surveillance of an
exposed population. In contrast, a bio-
marker ofeffect that is expressed long after
exposure could be ofrelatively little use in
exposure assessment, but be very useful in
predicting progression ofdisease or in cal-
culating risk. Animal models are useful for
understanding the mechanistic bases ofthe
expression of markers and relationships
between exposure, early effects, and dis-
ease. The validity ofa specific biomarker
of effect depends on the reliability of
studies that provide the background data,
particularly on mechanisms. Estimates of
the sensitivity ofa biomarker must include
its evaluation in an unexposed population
or unexposed animals to determine a base-
line value for the marker. This evaluation
may be difficult in the pediatric popula-
tion because of ethical issues involving
invasive procedures with little benefit to
the pediatric participant. Examples of two
biomarkers that have been extensively vali-
dated for both exposure and effect are
blood lead concentrations for both lead
exposure and lead neurotoxicity, and coti-
nine in serum, urine, and saliva for both
exposure to environmental tobacco smoke
and for predicting reduction in birth
weight. Examples of two biomarkers cur-
rently in the process ofvalidation include
dentin lead levels to predict elevated adult
body burden of lead (biomarker ofexpo-
sure) and reaction time on the Fagan Test
of Infant Intelligence to predict future





The identification of valid biomarkers
that indicate exposure, effect, or suscepti-
bility is a complicated process involving
studies in animals, refinements in labora-
tory assays, and studies in special human
populations. When validation has been
completed in such studies, the application
to larger populations is not straightfor-
ward. The Oversight Committee on
Biologic Markers (4) suggests the following
framework for implementing an identi-
fied, potentially informative biomarker in
large populations:
* Establish normal baseline values and
distribution for the marker in labora-
toryanimals and humans.
* Evaluate the sensitivityand specificity of
the marker in predicting a health out-
come (e.g., asthma orgenetic damage).
* Understand in detail the time course
of response of the marker to a toxic
chemical, with special attention to the
recoveryprocess.
* Develop a strategy for and a consensus
on the use ofmultiple species in toxico-
logic studies.
* Develop human assays that use semen,
saliva, or urine, rather than tissue or
blood, whenever possible.
* Use noninvasive techniques such as
ultrasound or magnetic resonance
imagingwhenever possible.
* Consider a batteryofmarkers that reflect
awide array ofphysiologic functions and
genetic damage and relate the marker in
question to others in thebattery.
* Identify populations at high risk for
reproductive or developmental health
impairment (perhaps populations
exposed to drugs with reproductive or
developmental toxicity, aging popula-
tions, or offspring ofwomen exposed to
diethylstilbestrol) to serve as test sub-
jects for the initial assessment and vali-
dation ofbiologic markers.
* Include among high-exposure popula-
tions those with special or unique occu-
pational exposures (e.g., children of
agricultural workers).
* Encourage and support institutions in
the development ofsample banks, to
speed the identification and validation
ofmarkers.




Work done by our laboratory and others
has demonstrated the usefulness of bio-
markers in pediatric environmental health.
Validation and use ofbiomarkers ofexpo-
sure, effect, and susceptibility in the areas
ofasthma/respiratory disease, cancer, and
neurodevelopmental effects would hasten
progress in understanding modes ofexpo-
sure and risk assessment for children.
Ongoingvalidation ofpromising biomarkers
should be a research priority.
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